TransCode Therapeutics (NASDAQ: RNAZ) announced significant advancements in its global intellectual property portfolio, including acceptance by IP Australia of Patent Application No. 2019349817 and the grant of Japanese Patent No. 7886877. These developments bolster the company’s position in the competitive field of RNA-based cancer therapies and could accelerate its path to commercialization.
The Australian patent application covers therapeutic nanoparticle compositions designed to deliver small interfering RNA (siRNA) molecules for cancer treatment. The allowed claims include nanoparticle compositions and methods of use across a range of cancers, including colon, lung, breast, pancreatic, and ovarian cancers. The application is expected to proceed to grant with a projected expiration date of September 6, 2039. This long-term protection could provide TransCode with a durable competitive advantage in the Australian market and beyond.
In Japan, TransCode received a Notice of Allowance from the Japan Patent Office, followed by the grant and issuance of Japanese Patent No. 7886877. This patent covers RNA-based immunomodulatory compositions designed to selectively activate innate immune pathways within tumors and the tumor microenvironment. The claims include compositions targeting cancers expressing miR-21 and nanoparticle-enabled delivery approaches incorporating magnetic or polymer-coated systems. This patent further solidifies TransCode’s intellectual property estate in a key Asian market.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead therapeutic candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The expansion of TransCode’s patent portfolio is crucial for attracting investment and partnerships in the highly competitive biotechnology sector. Intellectual property protection is often a key determinant of success for clinical-stage companies, as it provides exclusivity for their innovations and potential revenue streams. For investors, these patent allowances signal progress and validation of the company’s technology platform.
InvestorWire, a specialized communications platform, distributed the announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers a range of services including access to wire solutions, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit the full press release at https://ibn.fm/Pqy4e and the company’s newsroom at https://ibn.fm/RNAZ.
As TransCode continues to advance its pipeline, these patent milestones could pave the way for further clinical development and potential regulatory approvals. The company’s focus on RNA-based therapies aligns with broader industry trends toward targeted treatments that harness the body’s immune system to fight cancer. With a growing patent estate, TransCode is better positioned to navigate the complex landscape of drug development and commercialization.
